Table 3.
Pairwise Treatment Group Comparisons by Biomarker and Study Week
| Week 24 |
Week 48 |
Week 96 |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Biomarker | Mean (97.5% CI) | Pw Value | PFDR Value | Mean (97.5% CI) | Pw Value | PFDR Value | Mean (97.5% CI) | Pw Value | PFDR Value |
| ATV/r vs DRV/r | |||||||||
| hsCRP | 0.64 (.39, 1.04) | .039 | .58 | 0.53 (.32, .88) | .007 | .08 | |||
| IL-6 | 0.80 (.56, 1.14) | .15 | .58 | 0.89 (.62, 1.29) | .49 | .82 | |||
| D-dimer | 0.97 (.58, 1.61) | .78 | .99 | 0.74 (.45, 1.21) | .25 | .61 | |||
| GlycA | 0.98 (.92, 1.04) | .29 | .37 | ||||||
| sCD14 | 1.00 (.91, 1.09) | .96 | .99 | 1.00 (.89, 1.12) | .96 | .96 | |||
| sCD163 | 0.91 (.78, 1.06) | .12 | .58 | 0.87 (.73, 1.04) | .07 | .42 | |||
| sIL-2r | 0.99 (.80, 1.23) | .79 | .99 | 1.00 (.82, 1.22) | .72 | .96 | |||
| %CD4+: CD38+HLADR+ | 0.88 (.72, 1.08) | .18 | .32 | 0.90 (.70, 1.17) | .67 | .84 | |||
| %CD8+: CD38+HLADR+ | 0.95 (.80, 1.13) | .24 | .32 | 0.98 (.79, 1.20) | .55 | .84 | |||
| %MNC: CD14(dim)CD16+ | 1.01 (.91, 1.12) | .23 | .32 | 1.00 (.88, 1.14) | .32 | .76 | |||
| %MNC: CD14+CD16+ | 0.74 (.49, 1.10) | .08 | .31 | 0.82 (.55, 1.21) | .32 | .76 | |||
| ATV/r vs RAL | |||||||||
| hsCRP | 0.73 (.44, 1.22) | .60 | .77 | 0.97 (.59, 1.57) | .73 | .80 | |||
| IL-6 | 0.78 (.53, 1.13) | .16 | .43 | 1.14 (.85, 1.55) | .49 | .69 | |||
| D-dimer | 0.62 (.39, .99) | .015 | .13 | 0.59 (.38, .91) | .001 | .015 | |||
| GlycA | 0.99 (.93, 1.06) | .74 | .74 | ||||||
| sCD14 | 1.10 (1.00, 1.21) | .012 | .13 | 1.08 (.97, 1.20) | .06 | .13 | |||
| sCD163 | 0.95 (.82, 1.10) | .18 | .43 | 0.92 (.78, 1.08) | .09 | .19 | |||
| sIL-2r | 1.07 (.88, 1.31) | .48 | .71 | 1.06 (.87, 1.29) | .24 | .40 | |||
| %CD4+: CD38+HLADR+ | 0.88 (.71, 1.10) | .26 | .39 | 0.86 (.66, 1.11) | .42 | .77 | |||
| %CD8+: CD38+HLADR+ | 0.89 (.75, 1.06) | .11 | .23 | 0.93 (.73, 1.17) | .86 | .93 | |||
| %MNC: CD14(dim)CD16+ | 0.93 (.81, 1.06) | .68 | .68 | 0.99 (.88, 1.13) | .48 | .77 | |||
| %MNC: CD14+CD16+ | 0.62 (.41, .94) | .011 | .09 | 0.68 (.46, .99) | .007 | .06 | |||
| DRV/r vs RAL | |||||||||
| hsCRP | 1.14 (.74, 1.77) | .046 | .18 | 1.82 (1.16, 2.86) | <.001 | .012 | |||
| IL-6 | 0.98 (.68, 1.40) | .84 | .94 | 1.28 (.94, 1.74) | .12 | .28 | |||
| D-dimer | 0.64 (.41, 1.01) | .029 | .18 | 0.79 (.51, 1.21) | .046 | .15 | |||
| GlycA | 1.01 (.95, 1.08) | .52 | .55 | ||||||
| sCD14 | 1.10 (1.01, 1.20) | .008 | .07 | 1.08 (.98, 1.20) | .050 | .15 | |||
| sCD163 | 1.04 (.90, 1.20) | .99 | .99 | 1.06 (.89, 1.25) | .82 | .95 | |||
| sIL-2r | 1.08 (.89, 1.32) | .34 | .58 | 1.06 (.86, 1.31) | .41 | .55 | |||
| %CD4+: CD38+HLADR+ | 1.00 (.81, 1.24) | .98 | .98 | 0.95 (.73, 1.22) | .71 | .93 | |||
| %CD8+: CD38+HLADR+ | 0.94 (.80, 1.11) | .80 | .98 | 0.95 (.74, 1.21) | .81 | .93 | |||
| %MNC: CD14(dim)CD16+ | 0.92 (.81, 1.03) | .12 | .45 | 0.99 (.88, 1.12) | .68 | .93 | |||
| %MNC: CD14+CD16+ | 0.84 (.55, 1.30) | .25 | .50 | 0.83 (.54, 1.27) | .18 | .82 | |||
Relative mean fold-change from baseline with 97.5% confidence interval. Pairwise treatment group comparisons were separately conducted for the group of plasma biomarkers and for the group of GlycA and cellular biomarkers.
Values in italics indicate statistically significant observations.
Abbreviations: ATV/r, atazanavir/ritonavir; CI, confidence interval; DRV/r, darunavir/ritonavir; HLADR, human leukocyte antigen DR; hsCRP, high-sensitivity C-reactive protein; IL, interleukin; MNC, monocyte; PFDR, adjusted P values using Benjamini–Hochberg methods to control false discovery rate; Pw, unadjusted P values using Wilcoxon rank-sum test; RAL, raltegravir; sCD14, soluble CD14; sCD163, soluble CD163.